helmholtzeyeinstituteРоссийский офтальмологический журналRussian Ophthalmological Journal2072-00762587-5760Real time Publishers10.21516/2072-0076-2022-15-4-45-48helmholtzeyeinstitute-1096Research ArticleКЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯCLINICAL STUDIESОпыт применения препарата Луцентис в лечении ретинопатии недоношенныхApplying Lucentis for the treatment of retinopathy of prematurityЛесовойС. В.LesovoyS. V.

Сергей Валерьевич Лесовой — врач-офтальмохирург, заведующий офтальмологическим отделением

ул. Героев Панфиловцев, д. 28, Москва, 125373

Sergey V. Lesovoy — ophthalmic surgeon, head of the ophthalmological department

28, Geroev Panfilovtsev St., Moscow, 125373

sergforester1@mail.ruБогинскаяО. А.BoginskayaO. A.

Ольга Андреевна Богинская — канд. мед. наук, врач-офтальмолог офтальмологического отделения

ул. Героев Панфиловцев, д. 28, Москва, 125373

Olga A. Boginskaya — Cand. of Med. Sci., ophthalmologist, ophthalmological department

28, Geroev Panfilovtsev St., Moscow, 125373

ГБУЗ «Детская городская клиническая больница им. З.А. Башляевой» ДЗМРоссияZ.A. Bashlyaeva Children's City Clinical HospitalRussian Federation2022141220221544548Copyright © Лесовой С.В., Богинская О.А., 20222022Лесовой С.В., Богинская О.А.Lesovoy S.V., Boginskaya O.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://roj.igb.ru/jour/article/view/1096

Цель работы — оценить возможности применения препарата Луцентис в монотерапии активной фазы ретинопатии недоношенных (РН). Материал и методы. Интравитреальное введение препарата Луцентис (Швейцария, «Новартис Фарма») проведено 51 ребенку (102 глаза) с гестационным возрастом при рождении 24–33 нед. Критерием отбора пациентов являлось наличие РН I+, II+, III или III+ стадии в зоне 1, III+ стадии в зоне 2 или задней агрессивной РН (ЗАРН). Процедура выполнялась в условиях общей анестезии; лекарственная доза, методика и кратность введений соответствовали рекомендациям, указанным в инструкции к препарату. Профилактическая лазеркоагуляция после интравитреального введения луцентиса при наличии показаний осуществлялась на лазерных установках Supra (Quantel Medical, Франция) и «Лахта-Милон» (Россия, «Лазермедсервис»). Результаты. Клиническая эффективность интравитреального введения ранибизумаба у детей с ЗАРН, РН 1-й зоны, РН III стадии зоны 2 составляет 86,3 % (максимальное количество введений не превышало двух). Сохранение активности РН после двух введений является сигналом для смены терапии. Завершение васкуляризации отмечено в 51 % случаев. Заключение. Для достижения максимального эффекта лечения РН препаратом Луцентис необходимо строгое соблюдение критериев отбора пациентов.

Purpose: to evaluate the efficacy of Lucentis for the treatment of retinopathy of prematurity (ROP). Material and methods. 51 infants (102 eyes) with the gestational age between 24 and 33 weeks were given intravitreal injections of Lucentis, All patients selected had ROP stages I+, II+, III or III+ in zone 1, stage III+ in zone 2, or aggressive posterior ROP. The procedure was performed under general anesthesia; the dose, technique and the number of Lucentis injections conformed with the recommendations given in Lucentis instruction for use. If indicated, retinal laser photocoagulation was given after intravitreal injections using Supra (Quantel Medical, France) and Lachta-Mylon (Russia, Lasermedservis) laser equipment. Results. Clinical efficacy of intravitreal administration of Ranibizumab in infants with aggressive posterior ROP, zone 1 ROP, Stage III of zone 2 ROP was determined at 86.3 % (with no more than two injections). If ROP remains active after two injections, a change of therapy is recommended. Vascularization was noted to be complete in 51 % of cases. Conclusion. To achieve a maximum treatment effect of ROP with Lucentis, strict observation of indications criteria must take place.

ретинопатия недоношенныхингибиторы ангиогенезалуцентислазеркоагуляция сетчаткиretinopathy of prematurityvascular endothelial growth factor inhibitorsLucentisretinal photocoagulationReferencesDarlow B.A., Gilbert C. Retinopathy of prematurity — A world update. Semin. Perinatol. 2019; 43 (6): 315–6. doi:10.1053/j.semperi.2019.05.001Darlow B.A., Gilbert C. Retinopathy of prematurity — A world update. Semin. Perinatol. 2019; 43 (6): 315–6. doi:10.1053/j.semperi.2019.05.001Smith L.E., Hard A.L., Hellström A. The biology of retinopathy of prematurity: How knowledge of pathogenesis guides treatment. Clin. Perinatol. 2013; 40 (2): 201–14. doi:10.1016/j.clp.2013.02.002Smith L.E., Hard A.L., Hellström A. The biology of retinopathy of prematurity: How knowledge of pathogenesis guides treatment. Clin. Perinatol. 2013; 40 (2): 201–14. doi:10.1016/j.clp.2013.02.002Kim S.J., Port A.D., Swan R., et al. Retinopathy of prematurity: A review of risk factors and their clinical significance. Surv. Ophthalmol. 2018; 63 (5): 618–37. doi:10.1016/j.survophthal.2018.04.002Kim S.J., Port A.D., Swan R., et al. Retinopathy of prematurity: A review of risk factors and their clinical significance. Surv. Ophthalmol. 2018; 63 (5): 618–37. doi:10.1016/j.survophthal.2018.04.002Sankar M.J., Sankar J., Chandra P. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. Cochrane Database Syst. Rev. 2018; 1 (1): CD009734. doi:10.1002/14651858.CD009734.pub3Sankar M.J., Sankar J., Chandra P. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. Cochrane Database Syst. Rev. 2018; 1 (1): CD009734. doi:10.1002/14651858.CD009734.pub3Lepore D., Quinn G.E., Molle F., et al. Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings. Ophthalmology. 2018; 125 (2): 218–26. doi:10.1016/j.ophtha.2017.08.005Lepore D., Quinn G.E., Molle F., et al. Follow-up to age 4 years of treatment of type 1 retinopathy of prematurity intravitreal bevacizumab injection versus laser: fluorescein angiographic findings. Ophthalmology. 2018; 125 (2): 218–26. doi:10.1016/j.ophtha.2017.08.005Wong R.K., Hubschman S., Tsui I. Reactivation of retinopathy of prematurity after ranibizumab treatment. Retina. 2015; 35 (4): 675–80. doi:10.1097/IAE.0000000000000578Wong R.K., Hubschman S., Tsui I. Reactivation of retinopathy of prematurity after ranibizumab treatment. Retina. 2015; 35 (4): 675–80. doi:10.1097/IAE.0000000000000578Hartnett M.E. VEGF antagonist therapy for ROP. Clin. Perinatol. 2014; 41 (4): 925–43. doi:10.1016/j.clp.2014.08.011Hartnett M.E. VEGF antagonist therapy for ROP. Clin. Perinatol. 2014; 41 (4): 925–43. doi:10.1016/j.clp.2014.08.011Асташева И.Б., Шеверная О.А. Анализ эффективности применения различных видов офтальмокоагуляторов в лечении ретинопатии недоношенных. Российская детская офтальмология. 2014; 1: 25–9. [Astasheva I.B., Shevernaya O.A. Comparison of the laser photocoagulation types efficacy in the treatment of retinopathy of prematurity. Rossiyskaya detskaya oftalmologiya. 2014; 1: 25–9 (in Russian)].Astasheva I.B., Shevernaya O.A. Comparison of the laser photocoagulation types efficacy in the treatment of retinopathy of prematurity. Rossiyskaya detskaya oftalmologiya. 2014; 1: 25–9 (in Russian).Rybus-Kalinowska B., Kwiatkowski S., Chojnacka K., Jochem J. Retinopathy of prematurity – etiopathogenesis and treatment. Pediatr. Med. Rodz. 2017; 13 (1): 22–8. doi:10.15557/PiMR.2017.0002Rybus-Kalinowska B., Kwiatkowski S., Chojnacka K., Jochem J. Retinopathy of prematurity – etiopathogenesis and treatment. Pediatr. Med. Rodz. 2017; 13 (1): 22–8. doi:10.15557/PiMR.2017.0002Young T.L., Anthony D.C., Pierce E., Foley E., Smith L.E. Histopathology and vascular endothelial growth factor in untreated and diode laser-treated retinopathy of prematurity. J. AAPOS. 1997; 1 (2): 105–10. doi:10.1016/s1091-8531(97)90008-2Young T.L., Anthony D.C., Pierce E., Foley E., Smith L.E. Histopathology and vascular endothelial growth factor in untreated and diode laser-treated retinopathy of prematurity. J. AAPOS. 1997; 1 (2): 105–10. doi:10.1016/s1091-8531(97)90008-2Stefansson E. The therapeutic effects of retinal laser treatment and vitrectomy. A theory based on oxygen and vascular physiology. Acta Ophthalmol. Scand. 2001; 79 (5): 435–40. doi:10.1034/j.1600-0420.2001.790502.xStefansson E. The therapeutic effects of retinal laser treatment and vitrectomy. A theory based on oxygen and vascular physiology. Acta Ophthalmol. Scand. 2001; 79 (5): 435–40. doi:10.1034/j.1600-0420.2001.790502.xWang S., Zhang G., Shenzhen S. Screening for Retinopathy of Prematurity Cooperative Group Laser therapy versus intravitreal injection of anti-VEGF agents in monotherapy of ROP: a Meta-analysis. Int. J. Ophthalmol. 2020; 13 (5): 806–15. doi:10.18240/ijo.2020.05.17Wang S., Zhang G., Shenzhen S. Screening for Retinopathy of Prematurity Cooperative Group Laser therapy versus intravitreal injection of anti-VEGF agents in monotherapy of ROP: a Meta-analysis. Int. J. Ophthalmol. 2020; 13 (5): 806–15. doi:10.18240/ijo.2020.05.17Carroll L., Owen L.A. Current evidence and outcomes for retinopathy of prematurity prevention: insight into novel maternal and placental contributions. Explor. Med. 2020; 1: 4–26. doi:10.37349/emed.2020.00002Carroll L., Owen L.A. Current evidence and outcomes for retinopathy of prematurity prevention: insight into novel maternal and placental contributions. Explor. Med. 2020; 1: 4–26. doi:10.37349/emed.2020.00002Hard A., Hellström A. On the use of antiangiogenic medications for retinopathy of prematurity. Acta Paediatr. 2011; 100 (8): 1063–5. doi:10.1111/j.16512227.2011.02330.xHard A., Hellström A. On the use of antiangiogenic medications for retinopathy of prematurity. Acta Paediatr. 2011; 100 (8): 1063–5. doi:10.1111/j.16512227.2011.02330.xSato T., Wada K., Arahori H., et al. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am. J. Ophthalmol. 2012; 153 (2): 327–33. doi:10.1016/j.ajo.2011.07.005Sato T., Wada K., Arahori H., et al. Serum concentrations of bevacizumab (avastin) and vascular endothelial growth factor in infants with retinopathy of prematurity. Am. J. Ophthalmol. 2012; 153 (2): 327–33. doi:10.1016/j.ajo.2011.07.005Hoerster R., Muether P., Dahlke C., et al. Serum concentration of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity. Acta Ophthalmol. 2013; 91 (1): e 74–5. doi:10.1111/j.17553768.2012.02469.xHoerster R., Muether P., Dahlke C., et al. Serum concentration of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity. Acta Ophthalmol. 2013; 91 (1): e 74–5. doi:10.1111/j.17553768.2012.02469.xСадовникова Н.Н., Присич Н.В., Бржеский В.В. Анти-VEGF терапия ретинопатии недоношенных. Российская педиатрическая офтальмология. 2016; 11 (4): 212–20. [Sadovnikova N.N., Prisich N.V., Brzeskiy V.V. The role of VEGF inhibition in the treatment of retinopathy of prematurity. Rossiyskaya pediatricheskaya ophthalmologiya. 2016 11 (4): 212–20 (in Russian)]. doi:10.18821/1993-1859-2016-11-4-212-220Sadovnikova N.N., Prisich N.V., Brzeskiy V.V. The role of VEGF inhibition in the treatment of retinopathy of prematurity. Rossiyskaya pediatricheskaya ophthalmologiya. 2016 11 (4): 212–20 (in Russian). doi:10.18821/1993-1859-2016-11-4-212-220Сидоренко Е.Е., Назаренко А.О., Сидоренко Е.И., Обрубов С.А. Эффективность anti-VEGF-препарата Ранибизумаб при лечении ретинопатии недоношенных. Российская детская офтальмология. 2019; 3: 17–21. [Sidorenko E.E., Nazarenko A.O., Sidorenko E.I., Obrubov S.A. Anti-VEGF therapy by Ranibizumab in retinopathy of prematurity. Rossiyskaya detskaya ophthalmologiya. 2019; 3: 17–21 (in Russian)]. doi:10.25276/2307-6658-2019-3-17-21Sidorenko E.E., Nazarenko A.O., Sidorenko E.I., Obrubov S.A. Anti-VEGF therapy by Ranibizumab in retinopathy of prematurity. Rossiyskaya detskaya ophthalmologiya. 2019; 3: 17–21 (in Russian). doi:10.25276/2307-6658-2019-3-17-21Инструкция по медицинскому применению лекарственного препарата Луцентис. Регистрационный номер ЛСР-004567/08. 15.06.2020. [Product monograph Lucentis. Registration code: ЛСР-004567/08. 15.06.2020 (in Russian)]. Available at: https://www.novartis.ru/sites/www.novartis.ru/files/product-info/2020-06-15_Lucentis_NPI_v0.1-full_version.pdfProduct monograph Lucentis. Registration code: ЛСР-004567/08. 15.06.2020 (in Russian). Available at: https://www.novartis.ru/sites/www.novartis.ru/files/product-info/2020-06-15_Lucentis_NPI_v0.1-full_version.pdfTran K., Cernichiaro-Espinosa L.A., Berrocal A. Management of retinopathy of prematurity Use of Anti-VEGF therapy. Asia Pac. J. Ophthalmol. 2018; 7 (1): 5–62. doi:10.22608/APO.2017436Tran K., Cernichiaro-Espinosa L.A., Berrocal A. Management of retinopathy of prematurity Use of Anti-VEGF therapy. Asia Pac. J. Ophthalmol. 2018; 7 (1): 5–62. doi:10.22608/APO.2017436Menke M.N., Framme C., Nelle M., et al. Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3with plus disease. BMC Ophthalmol. 2015; 15: 20. doi:10.1186/s12886-015-0001-7Menke M.N., Framme C., Nelle M., et al. Intravitreal ranibizumab monotherapy to treat retinopathy of prematurity zone II, stage 3with plus disease. BMC Ophthalmol. 2015; 15: 20. doi:10.1186/s12886-015-0001-7Alyamac S.E., Gomez A., Kocluk Y., et al. The process of retinal vascularization after anti-VEGF treatment in retinopathy of prematurity: a comparison study between ranibizumab and bevacizumab. Ophthalmologica. 2016; 236: 139–47. doi:10.1159/000449530Alyamac S.E., Gomez A., Kocluk Y., et al. The process of retinal vascularization after anti-VEGF treatment in retinopathy of prematurity: a comparison study between ranibizumab and bevacizumab. Ophthalmologica. 2016; 236: 139–47. doi:10.1159/000449530Нероев В.В., Катаргина Л.А. Ретинопатия недоношенных, активная фаза. Клинические рекомендации; 2017. [Neroev V.V., Katargina L.A. Active phase of retinopathy of prematurity. Klinicheskie recomendacii; 2017 (in Russian)].Neroev V.V., Katargina L.A. Active phase of retinopathy of prematurity. Klinicheskie recomendacii; 2017 (in Russian).Beck K.D., Rahman E.Z., Ells A., et al. SAFER-ROP: Updated protocol for AntiVEGF injections for retinopathy of prematurity. Home ophthalmic surgery, lasers and imaging retina. 51 (7): 402–7. doi:10.3928/23258160-20200702-05Beck K.D., Rahman E.Z., Ells A., et al. SAFER-ROP: Updated protocol for AntiVEGF injections for retinopathy of prematurity. Home ophthalmic surgery, lasers and imaging retina. 51 (7): 402–7. doi:10.3928/23258160-20200702-05

The authors declare that there are no conflicts of interest present.